Abbott Labs beats forecasts, despite China woes
US health care firm Abbott Laboratories (NYSEL ABT), which last year spun off its research-based prescription medicines into AbbVie, reported third-quarter 2013 earnings from continuing operations of $773 million, or $0.49 per share, compared with $339 million, or $0.21 per share in the like, year-earlier period. Excluding special items, Abbott earnings per share were $0.55, beating analysts’ average expectations of $0. 51.
Third-quarter 2013 worldwide sales of $5.4 billion increased 4.3% on an operational basis, with strong performance in Diagnostics and Medical Devices. The sales disruption in International Nutrition – notably its infant formula business in China - is estimated to have reduced Abbott's total worldwide sales growth by nearly 2 percentage points. On a reported basis, sales increased 2.0%, including an unfavorable 2.3% effect of foreign exchange.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze